NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 21 04:00PM ET
6.45
Dollar change
+0.03
Percentage change
0.47
%
Index- P/E- EPS (ttm)-1.34 Insider Own11.64% Shs Outstand48.95M Perf Week19.67%
Market Cap329.96M Forward P/E27.10 EPS next Y0.24 Insider Trans-0.68% Shs Float45.20M Perf Month22.16%
Income-44.19M PEG- EPS next Q-0.38 Inst Own59.05% Short Float12.07% Perf Quarter10.82%
Sales0.00M P/S- EPS this Y66.24% Inst Trans-4.01% Short Ratio3.52 Perf Half Y10.07%
Book/sh0.85 P/B7.63 EPS next Y145.48% ROA-50.73% Short Interest5.45M Perf Year46.59%
Cash/sh1.65 P/C3.91 EPS next 5Y- ROE-271.78% 52W Range3.93 - 7.32 Perf YTD15.80%
Dividend Est.- P/FCF- EPS past 5Y47.21% ROI-78.05% 52W High-11.93% Beta1.57
Dividend TTM- Quick Ratio4.90 Sales past 5Y-15.07% Gross Margin- 52W Low64.01% ATR (14)0.50
Dividend Ex-Date- Current Ratio4.90 EPS Y/Y TTM72.26% Oper. Margin- RSI (14)62.49 Volatility8.42% 9.99%
Employees136 Debt/Eq0.58 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price19.93
Option/ShortYes / Yes LT Debt/Eq0.37 EPS Q/Q79.10% Payout- Rel Volume1.71 Prev Close6.42
Sales Surprise- EPS Surprise32.96% Sales Q/Q- EarningsMay 15 BMO Avg Volume1.55M Price6.45
SMA2010.12% SMA5021.84% SMA20014.31% Trades Volume2,665,714 Change0.47%
Date Action Analyst Rating Change Price Target Change
Mar-05-25Initiated Oppenheimer Outperform $16
Jul-03-24Initiated H.C. Wainwright Buy $15
May-30-24Initiated Stifel Buy $21
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
May-15-25 07:38AM
07:30AM
May-14-25 08:07AM
07:30AM
07:30AM
07:21AM Loading…
May-13-25 07:21AM
May-12-25 07:30AM
04:38AM
May-07-25 04:59PM
Apr-30-25 07:16AM
Apr-29-25 03:06PM
06:00AM
Apr-27-25 08:30AM
Apr-21-25 10:00AM
Apr-14-25 07:11AM
11:39AM Loading…
Apr-12-25 11:39AM
Apr-06-25 08:38AM
Apr-01-25 07:30AM
Mar-21-25 03:02AM
12:41AM
Mar-20-25 03:21PM
03:20PM
07:30AM
Mar-04-25 09:00AM
07:46AM
Mar-03-25 07:30AM
Feb-03-25 07:30AM
Dec-31-24 07:30AM
Dec-02-24 07:30AM
Nov-27-24 07:00AM
02:06AM Loading…
Nov-15-24 02:06AM
Nov-14-24 07:42AM
07:30AM
Nov-12-24 07:30AM
Nov-04-24 07:30AM
Nov-01-24 07:30AM
Oct-29-24 07:30AM
Oct-09-24 06:13PM
Oct-01-24 07:30AM
Sep-03-24 07:30AM
Sep-02-24 07:30AM
Aug-14-24 07:30AM
Aug-13-24 07:30AM
Aug-12-24 07:37AM
07:30AM
Aug-01-24 07:30AM
Jul-11-24 07:30AM
Jul-08-24 07:30AM
Jun-21-24 03:08AM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
02:17AM
May-15-24 12:53PM
07:43AM
07:30AM
May-07-24 07:30AM
May-03-24 11:19AM
07:30AM
Apr-23-24 02:04PM
08:53AM
07:39AM
07:09AM
Apr-22-24 05:58PM
04:27PM
04:14PM
04:05PM
Apr-01-24 08:30AM
Mar-19-24 06:53AM
05:31AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
07:30AM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
Nov-13-23 12:23PM
07:41AM
07:30AM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
07:30AM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
07:30AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
May-25-23 12:27AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alvino MarkDirectorMay 16 '25Sale5.688,00045,44092,435May 16 05:23 PM
Alvino MarkDirectorMay 16 '25Proposed Sale5.688,00045,423May 16 04:07 PM
Seshadri VishwasChief Executive OfficerMar 31 '25Sale4.7825,000119,5001,355,322Mar 31 07:17 PM
Seshadri VishwasOfficerMar 31 '25Proposed Sale4.7825,000119,560Mar 31 04:08 PM
Alvino MarkDirectorJan 29 '25Sale5.384,00021,52064,334Jan 31 04:30 PM
Alvino MarkOfficerJan 29 '25Proposed Sale5.414,00021,640Jan 29 04:03 PM
Alvino MarkDirectorJan 21 '25Sale5.104,00020,40068,334Jan 21 04:30 PM
Alvino MarkOfficerJan 21 '25Proposed Sale5.224,00020,880Jan 21 04:05 PM
Alvino MarkDirectorJun 18 '24Sale4.5125,890116,76436,926Jun 20 04:30 PM
Silverstein Christine BerniDirectorJun 18 '24Sale4.5125,821116,45362,063Jun 20 04:30 PM